

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jun 2026

### Effect of Nigella Sativa supplement on the expression of genes involved in insulin resistance and inflammation among obese women

#### Protocol summary

##### Study aim

Effect of Nigella Sativa supplement on the expression of genes involved in insulin resistance among obese women

##### Design

randomized double blind controlled clinical trial, cross-over

##### Settings and conduct

Of the obese women referring to the Imam Ali Clinic in Yazd, 40 people will be selected and randomly divided into two groups. The participants and investigator will not be aware of the drugs and placebo. The amount of genes expression in PBMC will be measured before and after the end of each stage of the intervention. Intervention is crossover and is performed in two stages of 8 weeks.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Obese women with BMI between 27 to 35 kg/m<sup>2</sup> and age between 25 to 55. Subjects should not use any drug. Should not have diabetes or pre-diabetes or dyslipidemia. Exclusion criteria: People who smoke or drink alcohol, pregnant and nursing women, People with chronic kidney or liver disease.

##### Intervention groups

Intervention group: capsule containing 1000 mg Nigella Sativa oil twice daily Control group: Placebo capsule containing paraffin oil twice daily

##### Main outcome variables

Expression of genes involved in insulin resistance in peripheral blood mononuclear cells; Fasting blood glucose; Serum insulin level; Serum leptin level; Serum IL-6 level;

#### General information

##### Reason for update

Measuring other factors related to Insulin Resistance in women with obesity and Overweight (funding provided)

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180430039475N1**

Registration date: **2018-06-25, 1397/04/04**

Registration timing: **prospective**

Last update: **2022-04-05, 1401/01/16**

Update count: **5**

##### Registration date

2018-06-25, 1397/04/04

##### Registrant information

###### Name

Sara Safi Esfahani

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 31 3230 5375

###### Email address

drsafi@ssu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-07-23, 1397/05/01

##### Expected recruitment end date

2019-03-20, 1397/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of Nigella Sativa supplement on the expression of genes involved in insulin resistance and inflammation among obese women

##### Public title

Effect of Nigella Sativa supplement on the expression of genes involved in insulin resistance

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Obese women with BMI between 27 to 35 kg/m<sup>2</sup> Age between 25 to 55 Should not use any drug Should not have diabetes or pre-diabetes or dyslipidemia

### Exclusion criteria:

People who smoke or drink alcohol Pregnant and nursing women People with chronic kidney, liver disease

## Age

From **25 years** old to **55 years** old

## Gender

Female

## Phase

3

## Groups that have been masked

- Participant
- Investigator
- Outcome assessor

## Sample size

Target sample size: **40**

More than 1 sample in each individual

Number of samples in each individual: **1**

Blood samples will be taken from all individuals before and after each period of interventions.

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization: Simple Random unit: Individual Tool: Randomized Tables A balanced block method is used to allocate concealment so that the number of samples assigned to each of the groups is equal.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

Supplements of cumin and placebo in the same capsules in terms of size, color and shape Encodes A and B on supplements and placebo

## Placebo

Used

## Assignment

Crossover

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Shahid Sadoughi University of Medical Sciences Yazd

##### Street address

School of health, Sadoughi University of Medical Sciences, Shohadaye Gornam Blvd., Alem Sq.

## City

Yazd

## Province

Yazd

## Postal code

8915173160

## Approval date

2018-04-17, 1397/01/28

## Ethics committee reference number

IR.SSU.SPH.REC.1397.006

## Health conditions studied

### 1

#### Description of health condition studied

Obesity

#### ICD-10 code

E66

#### ICD-10 code description

Overweight and obesity

## Primary outcomes

### 1

#### Description

Expression of genes involved in insulin resistance in peripheral blood mononuclear cells

#### Timepoint

at the beginning and end of each 2-month intervention period

#### Method of measurement

Reverse transcription polymerase chain reaction (RT-PCR)

### 2

#### Description

fasting blood glucose

#### Timepoint

at the beginning and end of each 2-month intervention period

#### Method of measurement

Biochemical analysis

### 3

#### Description

Serum insulin level

#### Timepoint

at the beginning and end of each 2-month intervention period

#### Method of measurement

ELISA Kit

### 4

#### Description

Serum malondialdehyde level

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

ELISA kit

**5****Description**

Serum total anti-oxidant capacity

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

ELISA kit

**6****Description**

serum leptin

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

ELISA kit

**7****Description**

serum IL-6

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

ELISA kit

**Secondary outcomes****1****Description**

Dietary intake

**Timepoint**

At the beginning and end of each 2-month intervention period

**Method of measurement**

three-day food records and 24-h food recalls questionnaires

**2****Description**

Expression of hormone-related genes in peripheral blood mononuclear cells

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

Reverse transcription polymerase chain reaction (RT-PCR)

**3****Description**

serum level of estradiol

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

ELISA kit

**4****Description**

serum level of sex-hormone binding globulin

**Timepoint**

at the beginning and end of each 2-month intervention period

**Method of measurement**

ELISA kit

**Intervention groups****1****Description**

Intervention group: People in this group will receive two 1000 mg capsules of Nigella Sativa daily for 8 weeks. Then it will be wash out period for 1 month, and after that, people will receive 2 placebo capsules daily for 8 weeks.

**Category**

Treatment - Drugs

**2****Description**

Control group: people in this group will receive two placebo capsules daily for 8 weeks. Then it will be wash out period for 1 month, and after that, people will receive two 1000 mg capsules of Nigella Sativa daily for 8 weeks.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Imam Ali clinic

**Full name of responsible person**

Sara Safi Esfahani

**Street address**

Navab Safavi Blvd.

**City**

Yazd

**Province**

Yazd

**Postal code**

8915173160

**Phone**

+98 35 3630 1700

**Email**

dr.s\_safi@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Research Associate, School of Health

**Street address**

Shohadaye gomnam Blvd., Shahid Sadoughi  
University of Medical Sciences, School of Health

**City**

Yazd

**Province**

Yazd

**Postal code**

8915173160

**Phone**

+98 35 3820 9100

**Email**

sphealth@ssu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Yazd University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Sara Safi Esfahani

**Position**

Phd Student

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Nutrition

**Street address**

School of health, Shahid Sadoughi university of  
medical sciences, Shohadaye Gomnam Blvd., Alam  
Sq,

**City**

Yazd

**Province**

Yazd

**Postal code**

8915173160

**Phone**

+98 35 3820 9100

**Email**

drsafi@ssu.ac.ir

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Azadeh Nadjarzadeh

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

School of health, Shahid Sadoughi university of  
medical sciences, Shohadaye Gomnam Blvd., Alam  
Sq,

**City**

Yazd

**Province**

Yazd

**Postal code**

8915173160

**Phone**

+98 35 3820 9100

**Email**

azadehnajarzadeh@gmail.com

## Person responsible for updating data

**Contact****Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Sara Safi Esfahani

**Position**

PhD Student

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Nutrition

**Street address**

School of health, Shahid Sadoughi university of  
medical sciences, Shohadaye Gomnam Blvd., Alam  
Sq,

**City**

Yazd

**Province**

Yazd

**Postal code**

8915173160

**Phone**

+98 35 3820 9100

**Email**

drsafi@ssu.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Not applicable

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

I have not yet decided on this.

**When the data will become available and for how long**

I have not yet decided on this.

**To whom data/document is available**

I have not yet decided on this.

**Under which criteria data/document could be used**

I have not yet decided on this.

**From where data/document is obtainable**

I have not yet decided on this.

**What processes are involved for a request to access data/document**

I have not yet decided on this.

**Comments**